002932 *ST明德生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-0.402-0.2901.2571.19690.614
总资产报酬率 ROA (%)-0.372-0.2621.0660.90466.739
投入资产回报率 ROIC (%)-0.396-0.2851.2321.13484.568

边际利润分析
销售毛利率 (%)45.81736.16553.89154.27866.846
营业利润率 (%)-7.761-29.57111.76619.37148.240
息税前利润/营业总收入 (%)-8.204-24.4656.53019.35647.876
净利润/营业总收入 (%)-14.934-28.3177.5899.23541.600

收益指标分析
经营活动净收益/利润总额(%)222.300209.087-254.38521.010118.847
价值变动净收益/利润总额(%)-261.293-162.969417.81889.4560.746
营业外收支净额/利润总额(%)27.332-22.873-27.057-3.792-0.068

偿债能力分析
流动比率 (X)18.62619.4334.8352.6983.248
速动比率 (X)18.15919.1624.6692.5713.139
资产负债率 (%)5.2325.4278.71214.81726.349
带息债务/全部投入资本 (%)0.4060.0270.4111.1316.906
股东权益/带息债务 (%)24,290.623361,385.86323,884.6368,631.6771,336.184
股东权益/负债合计 (%)1,771.3881,703.3591,014.342550.562268.294
利息保障倍数 (X)-3.31461.277-2.39227.931-144.295

营运能力分析
应收账款周转天数 (天)536.977835.7921,014.913905.10256.380
存货周转天数 (天)208.298156.791235.376203.37427.998